menu
    • menu

    Company profile for EyePoint Pharmaceuticals

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company has developed 5 FDA-approved sustained-release treatments in ophthalmology.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    EyePoint PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    480 Pleasant Street Suite B300 Watertown MA 02472 United States
    Telephone
    Telephone
    1-833-393-7646
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://eyepointpharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/eyepointpharmaceuticals/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/EyePointPharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Eyepoint Receives Positive Safety Committee Nod for Duravyu
    Eyepoint Receives Positive Safety Committee Nod for Duravyu

    19 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/19/3190786/0/en/EyePoint-Announces-Positive-Recommendation-from-Independent-Data-Safety-Monitoring-Committee-for-Pivotal-Phase-3-Trials-for-DURAVYU-in-Wet-Age-Related-Macular-Degeneration.html

    GLOBENEWSWIRE
    19 Nov 2025
    Share Share
    Eyepoint Discloses Inducement Grants Per NASDAQ LR 5635(C)(4)
    Eyepoint Discloses Inducement Grants Per NASDAQ LR 5635(C)(4)

    17 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/17/3188984/0/en/EyePoint-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    17 Nov 2025
    Share Share
    Eyepoint Unveils Q3 2025 Financials & Corporate Updates
    Eyepoint Unveils Q3 2025 Financials & Corporate Updates

    05 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/05/3181259/0/en/EyePoint-Reports-Third-Quarter-2025-Financial-Results-and-Highlights-Recent-Corporate-Developments.html

    GLOBENEWSWIRE
    05 Nov 2025
    Share Share
    Eyepoint To Release Q3 2025 Financial Results On November 5
    Eyepoint To Release Q3 2025 Financial Results On November 5

    29 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/29/3176260/0/en/EyePoint-to-Report-Third-Quarter-2025-Financial-Results-on-November-5-2025.html

    GLOBENEWSWIRE
    29 Oct 2025
    Share Share
    Eyepoint Discloses Inducement Grants Per NASDAQ LR 5635(C)(4)
    Eyepoint Discloses Inducement Grants Per NASDAQ LR 5635(C)(4)

    16 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/16/3167779/0/en/EyePoint-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    16 Oct 2025
    Share Share
    EyePoint Starts Ph3 DURAVYU Program in Diabetic Macular Edema
    EyePoint Starts Ph3 DURAVYU Program in Diabetic Macular Edema

    14 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/14/3166631/0/en/EyePoint-Announces-Pivotal-Phase-3-Program-Initiation-for-DURAVYU-in-Diabetic-Macular-Edema.html

    GLOBENEWSWIRE
    14 Oct 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search